1. Market Research
  2. > Pathology
64 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Prostate Cancer Therapeutics Industry

  • $ 5600
  • May 2019
  • 339 pages

Global Prostate Cancer Therapeutics Industry PROSTATE CANCER THERAPEUTICS MCP-## MARKET ANALYSIS, TRENDS, AND FORECASTS, MAY ## CONTENTS I.

  • Hormone
  • Lymphoma
  • Prostate Cancer
  • Therapy
  • Canada

2024 Canada Hematology and Flow Cytometry Analyzers and Reagents Market: Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Competitive Landscape, Emerging Technologies, Instrumentation and Opportunities

  • $ 1450
  • July 2020
  • 225 pages

Flow Cytometry Tests Analyzed in the Report Cell Surface Markers (CD##/ CD##/ TandB Lymphocytes, CD##, Others), Chemotherapy Monitoring (Leukemia/ Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analy

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Canada
  • Demand

2024 North America Hematology and Flow Cytometry Analyzers and Reagents Market: USA, Canada, Mexico

  • $ 7500
  • July 2020
  • 290 pages

Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analysis, Granulocyte Function, Receptor DNA/ RNA Analysis, Cell Culturing Instrumentation Review - Reviews of current instrumentation technologies, and featu

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Canada
  • North America

Canada Hematology and Flow Cytometry Analyzers and Reagents Market for Over 40 Tests: Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 750
  • September 2019
  • 225 pages

Flow Cytometry Tests Analyzed in the Report Cell Surface Markers (CD##/ CD##/ TandB Lymphocytes, CD##, Others), Chemotherapy Monitoring (Leukemia/ Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analy

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Canada
  • Demand

North America Hematology and Flow Cytometry Analyzers and Reagents Market for Over 40 Tests: USA, Canada, Mexico--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review, Emerging Opportunities

  • $ 7500
  • September 2019
  • 290 pages

Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analysis, Granulocyte Function, Receptor DNA/ RNA Analysis, Cell Culturing Instrumentation Review - Reviews of current instrumentation Technologies, and featu

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Canada
  • North America

Canada Hematology and Flow Cytometry Analyzers and Reagents Market, 2019-2023: Supplier Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 750
  • June 2019
  • 225 pages

Flow Cytometry Tests Analyzed in the Report Cell Surface Markers (CD##/ CD##/ TandB Lymphocytes, CD##, Others), Chemotherapy Monitoring (Leukemia/ Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analy

  • Biopharmaceutical
  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Canada

North America Hematology and Flow Cytometry Analyzers and Reagents Market, 2019-2023: USA, Canada, Mexico--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review, Emerging Opportunities

  • $ 7500
  • June 2019
  • 290 pages

Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analysis, Granulocyte Function, Receptor DNA/ RNA Analysis, Cell Culturing Instrumentation Review - Reviews of current instrumentation Technologies, and featu

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Canada
  • North America

Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • November 2018
  • 151 pages

ET AL. (2008) ' COMORBID CONDITIONS AND SURVIVAL IN UNSELECTED, NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA', LEUKEMIA AND LYMPHOMA, ##(##), PP. ##-##.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Canada

Analyzing Generics Market in Canada 2017

  • $ 850
  • August 2017
  • 90 pages

In February 2015, the company discontinued SAR-##, which was in Phase I trial for the treatment of advanced solid tumors or lymphomas, metastatic braf-mutated melanoma and PTEN deficient tumors.

  • Lymphoma
  • Pharmaceutical
  • Canada
  • Allergan plc
  • Apotex Inc.

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

  • $ 3995
  • November 2017
  • 47 pages

LEUKEMIA AND LYMPHOMA; ##(##):##-##.

  • Cancer
  • Leukemia
  • Lymphoma
  • Canada
  • Forecast

British Columbia Cancer Agency - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 20 pages

Buckstein of Sunnybrook Health Sciences Centre in Toronto, is working to improve outcomes in lymphoma patients over the age of ##.

  • Cancer
  • Healthcare
  • Lymphoma
  • Pathology
  • Canada

3D Signatures Inc (DXD) - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 42 pages

##D Signatures Inc (DXD) Medical Equipment - Deals and Alliances Profile October 2018 Report Code: GDME##D Published: ##D Signatures Inc (##D Signatures) is a developer of diagnostic and prognostic products for cancers and neurological disorders.

  • Lymphoma
  • Medical Device
  • Medical Equipment
  • Canada
  • Knight Therapeutics Inc.

Red Hill Iron Ltd. (Australia)

  • $ 1350
  • May 2016
  • 30 pages

Red Hill Iron Ltd.

  • Hormone
  • Lymphoma
  • Prostate Cancer
  • Therapy
  • Canada

Cancer Pain - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 148 pages

An activated Fractalkine system has been proposed by independent academic researchers to accelerate the progression of lymphoma by increasing blood flow into the tumor and/ or counteracting an attack from the patient' s immune system.

  • Analgesic
  • Biopharmaceutical
  • Cancer
  • Pharmaceutical
  • Canada

Aptose Biosciences Inc (APTO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 59 pages

Summary Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers.The company advances in ...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Canada
  • Aptose Biosciences Inc.

IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 60 pages

" We are focused on attracting and retaining the best employees for a clear purpose: to develop breakthrough immunotherapies for individuals living with serious medical conditions such as ovarian and lymphoma cancers.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Canada
  • Immunovaccine Inc.

NBE-Therapeutics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 20 pages

Summary NBE-Therapeutics AG (NBE-Therapeutics) is a biotechnology company that focuses on the development of antibody drug conjugates (ADC) to improve the treatment of cancer.ADCs act against cancer cells ...

  • Lymphoma
  • Therapy
  • Canada
  • Switzerland
  • Company

Sierra Oncology Inc (SRRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 48 pages

Mina Sooch, CEO of ProNAi, said, " This funding allows us to expand our current Phase II studies of PNT## as a single agent to those patients with refractory or relapsed diffuse large B-Cell lymphoma (DLBCL) and follicular lymphoma (FL).

  • Lymphoma
  • Oncology
  • Therapy
  • Canada
  • ProNAi Therapeutics, Inc.

Trillium Therapeutics Inc (TRIL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 47 pages

A two-part, multicenter, open-label, phase ##a/ ##b study of TTI-## in patients with advanced relapsed or refractory lymphoma or multiple myeloma is being initiated, with the first patient expected to be dosed in Q## 2018.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Canada
  • TTI

Canada Diagnostic Imaging Market Outlook to 2025 - Angio Suites, Bone Densitometers, C-Arms, Computed Tomography (CT) Systems and Others

  • $ 5995
  • June 2020
  • 237 pages

ONVANSERTIB HAS DEMONSTRATED SYNERGY IN PRECLINICAL STUDIES WITH NUMEROUS CHEMOTHERAPIES AND TARGETED THERAPEUTICS USED TO TREAT LEUKEMIAS, LYMPHOMAS AND SOLID TUMOR CANCERS, INCLUDING IRINOTECAN, FLT## AND HDAC INHIBITORS, TAXANES AND CYTOTOXINS.

  • CT Scan
  • Diagnostic Imaging
  • Hospital
  • Lymphoma
  • Canada
View report >

Medical Biotechnology Industry in Canada

  • August 2019
  • 76 pages

Lymphoma Canada is Canada' s only national organization focused entirely on lymphoma.

  • Immunotherapy
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • Canada

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on